Investor Presentaiton
Wound Care grew 5% in Q3, driven by double-digit growth in China,
while growth in Europe was held back by backorders
10
10
Wound & Skin Care performance
5-
1
14
13.
5
12
1
-5
4
-4
-6
747
700
695
688
678
•
Q3 2022/23 highlights
Wound and Skin Care grew 4%, while Wound Care in isolation grew 5%
China delivered double-digit growth in Q3 and benefited from a low
baseline. Hospital access and procedural volumes fully normalised
during Q3, positively impacting the demand for wound care products
US performed well and contributed nicely to growth
Good underlying momentum in Europe driven by the Biatain Silicone
portfolio, however, growth was held back by continued impact from
backorders, as expected
The resolution of the backorder situation is progressing as expected,
with limited backorder impact expected in Q4 2022/23
The Compeed contract manufacturing business detracted from growth in Q3
due to order phasing, while the underlying consumer demand remains healthy
Skin Care delivered a solid contribution to growth, and benefited from a lower
baseline last year
9
Q3 21/22
Q4 21/22 Q1 22/23
Q2 22/23 Q3 22/23
Revenues (DKKm)
Organic growth (%)
WC Organic growth (%)
Reported growth (%)
ColoplastView entire presentation